Stay updated with breaking news from Late Breaking. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs
November 16 Event to feature KOL perspective on Emerging HBV TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on...
–– Late-breaking results from Phase III trial of Ocrevus subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis will be presented –– 10-year Ocrevus...
–– Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented–– 10-year Ocrevus efficacy and safety data show significant benefit in slowing long-term disability progression and consistent lo...